InsiderTrades.com logo
Mark Ragosa net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mark Ragosa Biography and Net Worth

CFO of Kiniksa Pharmaceuticals

Mark joined Kiniksa prior to the company’s initial public offering in 2018. Mark oversees financial operations, investor relations, and information technology. Before his promotion to Chief Financial Officer in 2021, Mark served as the Vice President of Investor Relations and Finance. He joined Kiniksa from Ironwood Pharmaceuticals, where he was a member of the investor relations team. Prior to Ironwood, Mark was a vice president in the equities division at Goldman Sachs, where he built strategic relationships with key hedge fund and mutual fund companies and helped raise capital for private and public companies. Mark also held roles of increasing responsibility within the equities divisions of Morgan Stanley and Bank of America Securities. Mark has over 20 years of experience in the financial services and life sciences industries. He has a strong understanding of institutional investor needs as well as an extensive knowledge of finance and equity markets.

Mark holds a BA in government and history from Bowdoin College and is a Chartered Financial Analyst.

What is Mark Ragosa's net worth?

The estimated net worth of Mark Ragosa is at least $519,080.38 as of December 5th, 2024. Mr. Ragosa owns 22,958 shares of Kiniksa Pharmaceuticals stock worth more than $519,080 as of March 14th. This net worth approximation does not reflect any other assets that Mr. Ragosa may own. Learn More about Mark Ragosa's net worth.

How old is Mark Ragosa?

Mr. Ragosa is currently 50 years old. There are 4 older executives and no younger executives at Kiniksa Pharmaceuticals. The oldest executive at Kiniksa Pharmaceuticals is Dr. John F. Paolini FACC, M.D., Ph.D., Senior VP & Chief Medical Officer, who is 59 years old. Learn More on Mark Ragosa's age.

How do I contact Mark Ragosa?

The corporate mailing address for Mr. Ragosa and other Kiniksa Pharmaceuticals executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals can also be reached via phone at (781) 431-9100 and via email at ir@kiniksa.com. Learn More on Mark Ragosa's contact information.

Has Mark Ragosa been buying or selling shares of Kiniksa Pharmaceuticals?

Mark Ragosa has not been actively trading shares of Kiniksa Pharmaceuticals within the last three months. Most recently, Mark Ragosa sold 1,123 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $21.25, for a transaction totalling $23,863.75. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at $487,857.50. Learn More on Mark Ragosa's trading history.

Who are Kiniksa Pharmaceuticals' active insiders?

Kiniksa Pharmaceuticals' insider roster includes Michael Megna (Group Vice President of Finance and Chief Accounting Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Kiniksa Pharmaceuticals?

In the last year, insiders at the sold shares 11 times. They sold a total of 333,156 shares worth more than $8,367,632.36. The most recent insider tranaction occured on February, 10th when COO Eben Tessari sold 14,000 shares worth more than $273,980.00. Insiders at Kiniksa Pharmaceuticals own 54.6% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals.

Information on this page was last updated on 2/10/2025.

Mark Ragosa Insider Trading History at Kiniksa Pharmaceuticals

See Full Table

Mark Ragosa Buying and Selling Activity at Kiniksa Pharmaceuticals

This chart shows Mark Ragosa's buying and selling at Kiniksa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$600k-$400k-$200k$0$200k$400k$600kTotal Insider BuyingTotal Insider Selling

Kiniksa Pharmaceuticals Company Overview

Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Read More

Today's Range

Now: $22.61
Low: $22.02
High: $22.86

50 Day Range

MA: $19.95
Low: $18.17
High: $22.50

2 Week Range

Now: $22.61
Low: $16.56
High: $28.15

Volume

595,003 shs

Average Volume

407,191 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48